Cargando…

Disease course following High Disease Activity Status revealed patterns in SLE

BACKGROUND: We sought to examine the disease course of High Disease Activity Status (HDAS) patients and their different disease patterns in a real-world longitudinal cohort. Disease resolution till Lupus Low Disease Activity State (LLDAS) has been a general treatment goal, but there is limited infor...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoi, Alberta, Koelmeyer, Rachel, Bonin, Julie, Sun, Ying, Kao, Amy, Gunther, Oliver, Nim, Hieu T., Morand, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278658/
https://www.ncbi.nlm.nih.gov/pubmed/34261522
http://dx.doi.org/10.1186/s13075-021-02572-1
_version_ 1783722306065924096
author Hoi, Alberta
Koelmeyer, Rachel
Bonin, Julie
Sun, Ying
Kao, Amy
Gunther, Oliver
Nim, Hieu T.
Morand, Eric
author_facet Hoi, Alberta
Koelmeyer, Rachel
Bonin, Julie
Sun, Ying
Kao, Amy
Gunther, Oliver
Nim, Hieu T.
Morand, Eric
author_sort Hoi, Alberta
collection PubMed
description BACKGROUND: We sought to examine the disease course of High Disease Activity Status (HDAS) patients and their different disease patterns in a real-world longitudinal cohort. Disease resolution till Lupus Low Disease Activity State (LLDAS) has been a general treatment goal, but there is limited information on this subset of patients who achieve this. METHODS: All consenting patients of the Monash Lupus Cohort who had at least 12 months of observation were included. HDAS was defined as SLEDAI-2K ≥ 10 ever, and HDAS episode as the period from the first HDAS clinic visit until attainment of LLDAS. We examined the associations of different HDAS patterns with the likelihood of damage accrual. RESULTS: Of 342 SLE patients, 151 experienced HDAS at least once, accounting for 298 HDAS episodes. The majority of HDAS patients (76.2%) experienced Recurrent HDAS (> 1 HDAS visit), and a smaller subset (47.7%) had Persistent HDAS (consecutive HDAS visits for longer than 2 months). Recurrent or Persistent HDAS patients were younger at diagnosis and more likely to experience renal or serositis manifestations; persistent HDAS patients were also more likely to experience neurological manifestations. Baseline SLEDAI greater than 10 was associated with longer HDAS episodes. Recurrent and Persistent HDAS were both associated with an increased likelihood of damage accrual. The total duration of HDAS episode greater than 2 years and experiencing multiple HDAS episodes (≥4) was also associated with an increased likelihood of damage accrual (OR 1.80, 95% CI 1.08–2.97, p = 0.02, and OR 3.31, 95% CI 1.66–13.26, p = 0.01, respectively). CONCLUSION: HDAS episodes have a highly variable course. Recurrent and Persistent HDAS, and longer duration of HDAS episodes, increased the risk of damage accrual. In addition to a major signifier of severity in SLE, its resolution to LLDAS can determine the subsequent outcome in SLE patients.
format Online
Article
Text
id pubmed-8278658
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-82786582021-07-14 Disease course following High Disease Activity Status revealed patterns in SLE Hoi, Alberta Koelmeyer, Rachel Bonin, Julie Sun, Ying Kao, Amy Gunther, Oliver Nim, Hieu T. Morand, Eric Arthritis Res Ther Research Article BACKGROUND: We sought to examine the disease course of High Disease Activity Status (HDAS) patients and their different disease patterns in a real-world longitudinal cohort. Disease resolution till Lupus Low Disease Activity State (LLDAS) has been a general treatment goal, but there is limited information on this subset of patients who achieve this. METHODS: All consenting patients of the Monash Lupus Cohort who had at least 12 months of observation were included. HDAS was defined as SLEDAI-2K ≥ 10 ever, and HDAS episode as the period from the first HDAS clinic visit until attainment of LLDAS. We examined the associations of different HDAS patterns with the likelihood of damage accrual. RESULTS: Of 342 SLE patients, 151 experienced HDAS at least once, accounting for 298 HDAS episodes. The majority of HDAS patients (76.2%) experienced Recurrent HDAS (> 1 HDAS visit), and a smaller subset (47.7%) had Persistent HDAS (consecutive HDAS visits for longer than 2 months). Recurrent or Persistent HDAS patients were younger at diagnosis and more likely to experience renal or serositis manifestations; persistent HDAS patients were also more likely to experience neurological manifestations. Baseline SLEDAI greater than 10 was associated with longer HDAS episodes. Recurrent and Persistent HDAS were both associated with an increased likelihood of damage accrual. The total duration of HDAS episode greater than 2 years and experiencing multiple HDAS episodes (≥4) was also associated with an increased likelihood of damage accrual (OR 1.80, 95% CI 1.08–2.97, p = 0.02, and OR 3.31, 95% CI 1.66–13.26, p = 0.01, respectively). CONCLUSION: HDAS episodes have a highly variable course. Recurrent and Persistent HDAS, and longer duration of HDAS episodes, increased the risk of damage accrual. In addition to a major signifier of severity in SLE, its resolution to LLDAS can determine the subsequent outcome in SLE patients. BioMed Central 2021-07-14 2021 /pmc/articles/PMC8278658/ /pubmed/34261522 http://dx.doi.org/10.1186/s13075-021-02572-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Hoi, Alberta
Koelmeyer, Rachel
Bonin, Julie
Sun, Ying
Kao, Amy
Gunther, Oliver
Nim, Hieu T.
Morand, Eric
Disease course following High Disease Activity Status revealed patterns in SLE
title Disease course following High Disease Activity Status revealed patterns in SLE
title_full Disease course following High Disease Activity Status revealed patterns in SLE
title_fullStr Disease course following High Disease Activity Status revealed patterns in SLE
title_full_unstemmed Disease course following High Disease Activity Status revealed patterns in SLE
title_short Disease course following High Disease Activity Status revealed patterns in SLE
title_sort disease course following high disease activity status revealed patterns in sle
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8278658/
https://www.ncbi.nlm.nih.gov/pubmed/34261522
http://dx.doi.org/10.1186/s13075-021-02572-1
work_keys_str_mv AT hoialberta diseasecoursefollowinghighdiseaseactivitystatusrevealedpatternsinsle
AT koelmeyerrachel diseasecoursefollowinghighdiseaseactivitystatusrevealedpatternsinsle
AT boninjulie diseasecoursefollowinghighdiseaseactivitystatusrevealedpatternsinsle
AT sunying diseasecoursefollowinghighdiseaseactivitystatusrevealedpatternsinsle
AT kaoamy diseasecoursefollowinghighdiseaseactivitystatusrevealedpatternsinsle
AT guntheroliver diseasecoursefollowinghighdiseaseactivitystatusrevealedpatternsinsle
AT nimhieut diseasecoursefollowinghighdiseaseactivitystatusrevealedpatternsinsle
AT moranderic diseasecoursefollowinghighdiseaseactivitystatusrevealedpatternsinsle